Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥ 50% in Patients Treated in Quebec’s University Teaching Hospitals (DALP-First Study)

Since July 2017, pembrolizumab has been approved as a first-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with a PD-L1 score ≥ 50% in Quebec. Study objectives were to describe and assess the real-world use of pembrolizumab; report progression-free survival (PFS), overal...

Descripción completa

Detalles Bibliográficos
Autores principales: Bérard, Ghislain, Guévremont, Chantal, Marcotte, Nathalie, Schroeder, Coleen, Bouchard, Nicole, Rajan, Raghu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047395/
https://www.ncbi.nlm.nih.gov/pubmed/36975460
http://dx.doi.org/10.3390/curroncol30030247

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047395/
https://www.ncbi.nlm.nih.gov/pubmed/36975460
http://dx.doi.org/10.3390/curroncol30030247

Ejemplares similares